The abstract is read at the publisher; the summary is JClub's.
In adults aged 65–79 in the GALFLU trial, high-dose inactivated influenza vaccine is linked to a lower incidence of influenza- or pneumonia-related hospitalization, with >80% probability of benefit.
- Why it matters: The work addresses uncertainty in hospitalization benefit estimates for high-dose versus standard-dose influenza vaccination in older adults.
- What they did: A Bayesian re-analysis compared HD-IIV versus SD-IIV in the randomized GALFLU trial, quantifying the probability that relative vaccine effectiveness exceeded 10% for influenza- or pneumonia-related hospitalization.
- The result: The analysis supports benefit of HD-IIV over SD-IIV for these hospitalization outcomes, implying the high-dose formulation may reduce risk in this age group.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.